Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08JIV
|
|||
Former ID |
DAP000139
|
|||
Drug Name |
Amlodipine
|
|||
Synonyms |
Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hypertension [ICD-11: BA00-BA04] | Approved | [1], [2] | |
Therapeutic Class |
Antihypertensive Agents
|
|||
Company |
Dainippon Sumitomo
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H25ClN2O5
|
|||
Canonical SMILES |
CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
|
|||
InChI |
1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
|
|||
InChIKey |
HTIQEAQVCYTUBX-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 88150-42-9
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9043, 4436379, 7978692, 8151470, 11372046, 11374781, 11484087, 11488302, 11490819, 11492946, 12013616, 14781768, 29217715, 29221341, 46386686, 46507214, 47730753, 47730754, 48415556, 49681578, 50032146, 50111725, 50111726, 50946098, 51091781, 53787488, 56313574, 57321180, 85175495, 85789496, 85789660, 87322623, 92308659, 92308823, 92711323, 93166968, 104234246, 104299787, 117436332, 119525879, 124360696, 124659134, 124757688, 124799862, 124893198, 124893199, 125164492, 125336819, 125359103, 126525316
|
|||
ChEBI ID |
CHEBI:2668
|
|||
ADReCS Drug ID | BADD_D00121 ; BADD_D00122 | |||
SuperDrug ATC ID |
C08CA01
|
|||
SuperDrug CAS ID |
cas=088150429
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Metabolism of Drug Affected by Studied Microbe(s) | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
Studied Microbe: Gut microbiota unspecific | [3] | |||
Metabolic Reaction | Dehydrogenation | |||
Metabolic Effect | Decrease activity | |||
Description | Amlodipine can be metabolized by gut microbiota through dehydrogenation, which results in the decrease of the drug's activity. | |||
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridioides difficile was decreased by Amlodipine (adjusted p-values: 8.94E-03). | |||
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia hominis was decreased by Amlodipine (adjusted p-values: 1.26E-03). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) | Target Info | Blocker | [5], [6] |
KEGG Pathway | MAPK signaling pathway | |||
Cardiac muscle contraction | ||||
Adrenergic signaling in cardiomyocytes | ||||
Oxytocin signaling pathway | ||||
Hypertrophic cardiomyopathy (HCM) | ||||
Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
Dilated cardiomyopathy | ||||
Panther Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||
WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6981). | |||
REF 2 | Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. Curr Med Res Opin. 2009 Jan;25(1):177-85. | |||
REF 3 | Gut Microbiome and Response to Cardiovascular Drugs. Circ Genom Precis Med. 2019 Sep;12(9):421-429. | |||
REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 5 | A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94. | |||
REF 6 | Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loa... Eur J Pharmacol. 2008 Feb 2;580(1-2):201-13. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.